EDAP TMS (EDAP) Q1 2026 earnings summary

Executive summary

• Achieved record first quarter HIFU revenue of $11.6 million, up 78% year-over-year, marking the seventh consecutive quarter of HIFU revenue growth.

• U.S. HIFU procedures grew 53% year-over-year, with Focal One system shipments up 83% year-over-year.

• Total worldwide revenue reached $17.8 million, a 24% increase compared to the same quarter last year.

• Gross profit margin improved to 45.7% from 42.0% year-over-year, driven by favorable product mix and higher HIFU sales.

• Net loss widened to $9.1 million, or ($0.24) per share, compared to $7.4 million, or ($0.20) per share, in the prior year.

Financial highlights

• HIFU business revenue: $11.6 million, up 78% year-over-year.

• Non-core ESWL and Distribution revenue: $6.2 million, down from $7.8 million year-over-year.

• Gross profit: $8.1 million (45.7% margin), up from $6.0 million (42.0%) year-over-year.

• Operating loss: $7.4 million, compared to $6.3 million last year.

• Net loss: $9.1 million, or ($0.24) per share, versus $7.4 million, or ($0.20) per share, last year.

Outlook and guidance

• Reiterated 2026 core HIFU business revenue guidance of $50.0–$54.0 million, representing 34–45% year-over-year growth.

• Non-core ESWL and Distribution revenue expected between $22.0–$26.0 million.